Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Annals of the Rheumatic DiseasesPublished 29 October 2015Open access
Gerd R Burmester, William F. C. Rigby, Ronald van Vollenhoven, Jonathan Kay, Andrea Rubbert‐Roth, Ariella Kelman
Citations192
SJR quartileQ1
SJR score5.73
SNIP4.44
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
TCZ is effective in combination with MTX and as monotherapy for the treatment of patients with early RA and demonstrated clinical efficacy that was at least as effective as MTX for these key secondary endpoints.
Abstract
ClinicalTrials.gov, number NCT01007435.
Keywords
Medicine
Annals of the Rheumatic DiseasesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
5,775 Citations2017Josef S Smolen, Robert Landewé +47 more
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Annals of the Rheumatic Diseases2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
4,875 Citations2010D. Aletaha, Tuhina Neogi +33 more
Arthritis Care & Research2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
1,792 Citations2012Jasvinder A. Singh, Daniel E. Fürst +28 more
The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Arthritis & RheumatismThe PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
1,786 Citations2005Ferdinand C. Breedveld, Michael H. Weisman +7 more
Combination therapy with adalimumab plus MTX was significantly superior to either MTX alone or ad alimumab alone in improving signs and symptoms of disease, inhibiting radiographic progression, and effecting clinical remission in patients with early, aggressive rheumatoid arthritis.
Annals of the Rheumatic DiseasesEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
1,762 Citations2013Josef S Smolen, Robert Landewé +31 more
The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA.
The LancetEffect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
1,386 Citations2008Josef S Smolen, André Beaulieu +6 more
Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis.
Arthritis & RheumatismCombination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
1,166 Citations2004E. William St. Clair, Désirée van der Heijde +12 more
For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment withMTX alone.
Annals of the Rheumatic DiseasesIL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
1,091 Citations2008Paul Emery, Edward Keystone +7 more
Tocilizumab plus methotrexate is effective in achieving rapid and sustained improvements in signs and symptoms of RA in patients with inadequate response to TNF antagonists and has a manageable safety profile.
Arthritis & RheumatismInterleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study
858 Citations2008Mark C. Genovese, James D. McKay +6 more
Tocilizumab combined with any of the DMARDs evaluated was safe and effective in reducing articular and systemic symptoms in patients with an inadequate response to these agents.
Arthritis & RheumatismInterleukin‐6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
854 Citations1988Frédéric Houssiau, Jean‐Pierre Devogelaer +3 more
There is a significant correlation between serum IL-6 activity and serum levels of C-reactive protein, alpha 1-acid glycoprotein,alpha 1-antitrypsin, fibrinogen, and haptoglobin, which indicates that IL- 6 is related to disease activity in patients with RA.
BloodMechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
810 Citations2008Norihiro Nishimoto, Kimio Terao +4 more
Serum IL-6 and sIL-6R markedly increased after tocilizumab administration in patients with rheumatoid arthritis and Castleman disease and the increased level of free IL-8 during tocilIZumab treatment closely reflects the actual endogenous IL- 6 production and true disease activity.
Annals of the Rheumatic DiseasesComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
789 Citations2009Graeme Jones, Anthony Sebba +9 more
Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed.
The LancetTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
663 Citations2013Cem Gabay, Paul Emery +9 more
Tocilizumab monotherapy was superior to adalimumabmonotherapy for reduction of signs and symptoms of rheumatoid arthritis in patients for whom methotrexate was deemed inappropriate.
Arthritis & RheumatismTocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
410 Citations2010Joel M. Kremer, Ricardo Blanco +6 more
The findings of this study show that tocilizumab plus MTX results in greater inhibition of joint damage and improvement in physical function than does MTX alone.
Arthritis & RheumatismGolimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
396 Citations2009Paul Emery, Roy Fleischmann +13 more
The modified ITT analysis of the primary end point and other prespecified efficacy measures demonstrated that the efficacy of golimumab plus MTX is better than, and the efficacious of Golimumab alone is similar to, the effectiveness of MTX alone in reducing RA signs and symptoms in MTX-naive patients, with no unexpected safety concerns.
Annals of the Rheumatic DiseasesClinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
346 Citations2009René Westhovens, M. Robles +15 more
In a methotrexate-naive population with early RA and poor prognostic factors, the combination of abatacept and methotRexate provided significantly better clinical and radiographic efficacy compared with methot Rexate alone and had a comparable, favourable safety profile.
Annals of the Rheumatic DiseasesInhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
300 Citations2010Paul P. Tak, William F. C. Rigby +8 more
Treatment with rituximab 2×1000 mg in combination withMTX is an effective therapy for the treatment of patients with MTX-naïve RA.
Annals of the Rheumatic DiseasesAdding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
285 Citations2012Maxime Dougados, K. Kissel +10 more
No clinically relevant superiority of the TCZ+MTX add-on strategy over the switch to tocilizumab monotherapy strategy was observed and Meaningful clinical and radiographic responses were achieved with both strategies, suggesting that tocilizumab monotherapy might be a valuable treatment strategy in suitable RA patients.
Arthritis & RheumatismRadiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
278 Citations1998Frederick Wolfe, John T. Sharp
Radiographic damage occurs at a constant rate in RA, and is not greater early in RA or reduced later in the course of the illness, as measured by the summary Sharp scores.
Lara D. VeekenTherapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
267 Citations2009Jean‐Michel Dayer, Ernest Choy
Elevated levels of IL-6 and sIL-6R in the SF of RA patients can increase the risk of joint destruction and, at the joint level, IL- 6/sIL- 6R can stimulate pannus development through increased VEGF expression and increase bone resorption as a result of osteoclastogenesis.
Arthritis & RheumatismHead‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
248 Citations2012Michael E. Weinblatt, Michael Schiff +6 more
Annals of the Rheumatic DiseasesEfficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
228 Citations2014Gerd‐Rüdiger Burmester, Alan Kivitz +6 more
Annals of the Rheumatic DiseasesCourse of radiographic damage over 10 years in a cohort with early rheumatoid arthritis
198 Citations2003Elisabet Lindqvist, K Jonsson +2 more
Joint damage in hands and feet developed early and progression was most rapid during the first years of disease, and it was not possible to predict non-progressive disease.
PubMedLongterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.
123 Citations2005Mark C. Genovese, Joan M. Bathon +6 more
Etanercept treatment in patients with early RA was generally well tolerated for up to 5 years, indicating sustained efficacy and decreased rate of radiographic progression.
Arthritis & RheumatismTwo‐year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two‐year, double‐blind, randomized study
115 Citations2010Paul Emery, Ferdinand C. Breedveld +7 more
Early sustained combination etanercept-MTX therapy was consistently superior to MTX monotherapy, and resulted in important clinical and radiographic benefits over 2 study years, without significant additional safety risk.
Annals of the Rheumatic DiseasesSerum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort
90 Citations2012Jacques‐Eric Gottenberg, Jean‐Michel Dayer +7 more
Serum IL-6 and IL-21 were the only cytokines that discriminated RA from UA on univariate analysis, andIL-6 level was associated with RA, whereas erythrocyte sedimentation rate and C-reactive protein were not.
Expert Review of Clinical PharmacologyClinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis
43 Citations2011Xiaoping Zhang, Richard Peck
Tocilizumab exposures are not affected by common concomitant medications in RA patients, but decreased IL-6 activity resulted in increased CYP3A4 activity and hence decreased exposures of CYP 3A4 substrates.